Addendum: A phase II trial of cytoreductive surgery combined with niraparib maintenance in platinum-sensitive, secondary recurrent ovarian cancer: SGOG SOC-3 study
1 Ovarian Cancer Program, Department of Gynecologic Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
2 Department of Gynecologic Oncology, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, China.
3 Department of Gynecologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.
4 Department of Gynecologic Oncology, Fudan University Cancer Hospital, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
5 Department of Gynecology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China.
6 Department of Obstetrics and Gynecology, Xin Hua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
7 Department of Obstetrics and Gynecology, Shanghai General Hospital, Shanghai, China.
8 Department of Obstetrics and Gynecology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
9 Department of Biostatistics, Fudan University, Shanghai, China.
10 Clinical Statistics Center, Shanghai General Hospital, Shanghai, China.